Released Feb 26, 2025, after the close
10-K filed Mar 11, 2025, 70 days after period end · 0000950170-25-036608
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$890.00K$890.00K derived−96.8% vs Q4 2023−96.0% vs Q3 2024
Net Income-$34.07M-$34.07M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$1,805,000N/M
Operating Incomederived-$10,343,000N/M
Operating Cash Flowderived-$14,059,000N/M
Free Cash Flowderived-$17,441,000N/M
Margins · derived
Gross margin-202.8%−250.4 pt vs Q4 2023
Operating margin-1162.1%−1086.3 pt vs Q4 2023
Net margin-3828.3%−3758.2 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $890.00K | $28.19M | $27.02M | $38.27M |
| Net Income | -$34.07M | -$19.78M | -$20.85M | -$9.43M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR